Compare Heron Therapeutics Inc (HRTX) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Manchester United PLC — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Manchester United PLC trades at $20.59 (market cap $3.51B). The key difference: Manchester United PLC is far larger — about 51.6× Heron Therapeutics Inc's market cap, and Manchester United PLC pays a 1.26% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Manchester United PLC for 109 Days on average.
| HRTX | MANU | |
|---|---|---|
Market Cap | $68.01M | $3.51B |
Volume | 1,891,941 | 412,769 |
Sector | Health | Media |
52-Week High | $1.49 | $24.19 |
52-Week Low | $0.27 | $15.20 |
Typical Hold Time | 35 Days | 109 Days |
Enterprise Value | $174.75M | $4.33B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Manchester United (MANU) trades at $20.60, up 1.73% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $666.51M in 2025 but negative net income margins and ROE. Analyst sentiment is divided with 40% buy ratings, while cash flow trends show heavy investment spending offset by financing activities.
The stock presents a valuation disconnect opportunity with market cap below Forbes' franchise estimates, but faces execution risks from persistent losses and high debt load. Upside depends on Champions League revenue conversion and cost management, while downside risks include sustained profitability challenges in the competitive sports landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
